Breathe Easy

Alleviate the signs of asthma with Aservo^® EquiHaler^®

A unique way to treat severe equine asthma

For horses and ponies held back by equine asthma, it’s important to treat their lower airway inflammation and manage the allergens in their environment in order to restore their freedom.

Historically, treating lower airway inflammation effectively with corticosteroids has been a challenge because of the effects these medicines can have on the rest of the body. Now the Aservo^® EquiHaler^® provides effective corticosteroid treatment specifically targeted to the lungs, allowing horses and ponies with equine asthma to breathe comfortably while reducing the risks you may have associated with giving steroids in the past.

Designed for horses and the people who care for them

The Aservo^® EquiHaler^® is designed specifically for use in horses.

In clinical trials, 95% of horses accepted the treatment with 93% compliance from the owner.³ To get the best results with your patients we have a range of materials to support you and your clients but first read on to find out why it’s worth teaching your clients how to use the EquiHaler^®.

CLICK HERE TO ACCESS SUPPORT FOR YOUR CLIENTS CLICK HERE TO LEARN HOW TO USE THE EQUIHALER^®

Soft Mist™ Technology = small particle size x low velocity

We are here to help

To be contacted by a BI representative contact us by clicking the link below, or email vetenquiries@boehringer-ingelheim.com.

References

Dalby, R., Spallek, M. and Voshaar, T. (2004) ‘A review of the development of Respimat^® Soft Mist^™ Inhaler’, International Journal of Pharmaceutics, 283(1-2), pp.1-9.
Lavoie, J.P. et al. (2019) ‘Effect of different doses of inhaled ciclesonide on lung function, clinical signs related to airflow limitation and serum cortisol levels in horses with experimentally induced mild to severe airway obstruction’, Equine Veterinary Journal, 51, pp. 779-786.
CVMP assessment report for Aservo^® EquiHaler^®.
Mukker,J.K., Singh, R.S.P. and Derendorf, H. (2016) 'Ciclesonide: a pro-soft drug approach for mitigation of side effects of inhaled corticosteroids', Journal of Pharmaceutical Sciences, 105, pp. 2509-2514.
Hänsel, M., Bambach, T. and Wachtel, H. (2019) ‘Reduced Environmental Impact of the Reusable Respimat^® Soft Mist™ Inhaler Compared with Pressurised Metered-Dose Inhalers’, Advances in therapy, 36(9), pp.2487-2492.
Capstick, T.G.D. and Clifton, I.J. (2012) ‘Inhaler technique and training in people with chronic obstructive pulmonary disease and asthma’, Expert Review of Respiratory Medicine, 6(1), pp. 91-103.
Eicher, J et al (2011) Development of Respimat Soft Mist™ inhaler and its clinical utility in respiratory disorders, Medical Devices (Auckland) 4 pp145-155.
Pirie, R.S. and McGorum, B.C. (2017) Inhalation therapy for equine lower respiratory tract disease In Practice, 39(7) pp317-327.

Aservo^® EquiHaler^® 343 micrograms/actuation inhalation solution for horses contains ciclesonide. UK: POM-V IE: POM. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. UK Tel: 01344 746960 (sales) or 01344 746957 (technical), IE Tel: 01 291 3985 (all queries). Email:vetenquiries@boehringer-ingelheim.com. Aservo^® EquiHaler^® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under licence. ©2023 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: October 2023. UI-EQU-0119-2020. Use Medicines Responsibly.